Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program

Richard R. Rubin, Yong Ma, David Marrero, Mark Peyrot, Elizabeth L. Barrett-Connor, Steven E. Kahn, Steven M. Haffner, David W. Price, William C. Knowler

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

OBJECTIVE - To assess the association between elevated depression symptoms or antidepressant medicine use on entry to the Diabetes Prevention Program (DPP) and during the study and the risk of developing diabetes during the study. RESEARCH DESIGN AND METHODS - DPP participants (n = 3,187) in three treatment arms (intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout the study (average duration in study 3.2 years). RESULTS - When other factors associated with the risk of developing diabetes were controlled, elevated BDI scores at baseline or during the study were not associated with diabetes risk in any arm. Baseline antidepressant use was associated with diabetes risk in the PLB (hazard ratio 2.25 [95% CI 1.38-3.66]) and ILS (3.48 [1.93-6.28]) arms. Continuous antidepressant use during the study (compared with no use) was also associated with diabetes risk in the same arms (PLB 2.60 [1.37-4.94]; ILS 3.39 [1.61-7.13]), as was intermittent antidepressant use during the study in the ILS arm (2.07 [1.18-3.62]). Among MET arm participants, antidepressant use was not associated with developing diabetes. CONCLUSIONS - A strong and statistically significant association between antidepressant use and diabetes risk in the PLB and ILS arms was not accounted for by measured confounders or mediators. If future research finds that antidepressant use independently predicts diabetes risk, efforts to minimize the negative effects of antidepressant agents on glycemic control should be pursued.

Original languageEnglish
Pages (from-to)420-426
Number of pages7
JournalDiabetes Care
Volume31
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Antidepressive Agents
Medicine
Depression
Life Style
Placebos
Metformin
Equipment and Supplies
Random Allocation
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. / Rubin, Richard R.; Ma, Yong; Marrero, David; Peyrot, Mark; Barrett-Connor, Elizabeth L.; Kahn, Steven E.; Haffner, Steven M.; Price, David W.; Knowler, William C.

In: Diabetes Care, Vol. 31, No. 3, 03.2008, p. 420-426.

Research output: Contribution to journalArticle

Rubin, RR, Ma, Y, Marrero, D, Peyrot, M, Barrett-Connor, EL, Kahn, SE, Haffner, SM, Price, DW & Knowler, WC 2008, 'Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program', Diabetes Care, vol. 31, no. 3, pp. 420-426. https://doi.org/10.2337/dc07-1827
Rubin, Richard R. ; Ma, Yong ; Marrero, David ; Peyrot, Mark ; Barrett-Connor, Elizabeth L. ; Kahn, Steven E. ; Haffner, Steven M. ; Price, David W. ; Knowler, William C. / Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. In: Diabetes Care. 2008 ; Vol. 31, No. 3. pp. 420-426.
@article{950213e6d6af446c8a167a6102adcc94,
title = "Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program",
abstract = "OBJECTIVE - To assess the association between elevated depression symptoms or antidepressant medicine use on entry to the Diabetes Prevention Program (DPP) and during the study and the risk of developing diabetes during the study. RESEARCH DESIGN AND METHODS - DPP participants (n = 3,187) in three treatment arms (intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout the study (average duration in study 3.2 years). RESULTS - When other factors associated with the risk of developing diabetes were controlled, elevated BDI scores at baseline or during the study were not associated with diabetes risk in any arm. Baseline antidepressant use was associated with diabetes risk in the PLB (hazard ratio 2.25 [95{\%} CI 1.38-3.66]) and ILS (3.48 [1.93-6.28]) arms. Continuous antidepressant use during the study (compared with no use) was also associated with diabetes risk in the same arms (PLB 2.60 [1.37-4.94]; ILS 3.39 [1.61-7.13]), as was intermittent antidepressant use during the study in the ILS arm (2.07 [1.18-3.62]). Among MET arm participants, antidepressant use was not associated with developing diabetes. CONCLUSIONS - A strong and statistically significant association between antidepressant use and diabetes risk in the PLB and ILS arms was not accounted for by measured confounders or mediators. If future research finds that antidepressant use independently predicts diabetes risk, efforts to minimize the negative effects of antidepressant agents on glycemic control should be pursued.",
author = "Rubin, {Richard R.} and Yong Ma and David Marrero and Mark Peyrot and Barrett-Connor, {Elizabeth L.} and Kahn, {Steven E.} and Haffner, {Steven M.} and Price, {David W.} and Knowler, {William C.}",
year = "2008",
month = "3",
doi = "10.2337/dc07-1827",
language = "English",
volume = "31",
pages = "420--426",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program

AU - Rubin, Richard R.

AU - Ma, Yong

AU - Marrero, David

AU - Peyrot, Mark

AU - Barrett-Connor, Elizabeth L.

AU - Kahn, Steven E.

AU - Haffner, Steven M.

AU - Price, David W.

AU - Knowler, William C.

PY - 2008/3

Y1 - 2008/3

N2 - OBJECTIVE - To assess the association between elevated depression symptoms or antidepressant medicine use on entry to the Diabetes Prevention Program (DPP) and during the study and the risk of developing diabetes during the study. RESEARCH DESIGN AND METHODS - DPP participants (n = 3,187) in three treatment arms (intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout the study (average duration in study 3.2 years). RESULTS - When other factors associated with the risk of developing diabetes were controlled, elevated BDI scores at baseline or during the study were not associated with diabetes risk in any arm. Baseline antidepressant use was associated with diabetes risk in the PLB (hazard ratio 2.25 [95% CI 1.38-3.66]) and ILS (3.48 [1.93-6.28]) arms. Continuous antidepressant use during the study (compared with no use) was also associated with diabetes risk in the same arms (PLB 2.60 [1.37-4.94]; ILS 3.39 [1.61-7.13]), as was intermittent antidepressant use during the study in the ILS arm (2.07 [1.18-3.62]). Among MET arm participants, antidepressant use was not associated with developing diabetes. CONCLUSIONS - A strong and statistically significant association between antidepressant use and diabetes risk in the PLB and ILS arms was not accounted for by measured confounders or mediators. If future research finds that antidepressant use independently predicts diabetes risk, efforts to minimize the negative effects of antidepressant agents on glycemic control should be pursued.

AB - OBJECTIVE - To assess the association between elevated depression symptoms or antidepressant medicine use on entry to the Diabetes Prevention Program (DPP) and during the study and the risk of developing diabetes during the study. RESEARCH DESIGN AND METHODS - DPP participants (n = 3,187) in three treatment arms (intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout the study (average duration in study 3.2 years). RESULTS - When other factors associated with the risk of developing diabetes were controlled, elevated BDI scores at baseline or during the study were not associated with diabetes risk in any arm. Baseline antidepressant use was associated with diabetes risk in the PLB (hazard ratio 2.25 [95% CI 1.38-3.66]) and ILS (3.48 [1.93-6.28]) arms. Continuous antidepressant use during the study (compared with no use) was also associated with diabetes risk in the same arms (PLB 2.60 [1.37-4.94]; ILS 3.39 [1.61-7.13]), as was intermittent antidepressant use during the study in the ILS arm (2.07 [1.18-3.62]). Among MET arm participants, antidepressant use was not associated with developing diabetes. CONCLUSIONS - A strong and statistically significant association between antidepressant use and diabetes risk in the PLB and ILS arms was not accounted for by measured confounders or mediators. If future research finds that antidepressant use independently predicts diabetes risk, efforts to minimize the negative effects of antidepressant agents on glycemic control should be pursued.

UR - http://www.scopus.com/inward/record.url?scp=44449103813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449103813&partnerID=8YFLogxK

U2 - 10.2337/dc07-1827

DO - 10.2337/dc07-1827

M3 - Article

C2 - 18071002

AN - SCOPUS:44449103813

VL - 31

SP - 420

EP - 426

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -